Argus Says Abbott Laboratories Shares Favorably Valued Despite 'Heightened' M&A Risks
July 27, 2016 at 16:10 PM EDT
Argus maintains its Buy rating and $55 price target on Abbott Laboratories (NYSE: ABT) after it posted better-than-expected ...